Cyprotex are proud to announce the launch of an enhanced Cloe® Select experimental service to evaluate human cytochrome P450 induction - an important factor in determining the likelihood of clinical drug-drug interactions. The consequences of induction in the clinic may be therapeutic failure caused by a decreased systemic exposure of the drug itself or a co-administered therapy, or toxicity as a result of increased bioactivation.
According to the PhRMA perspective published earlier this year (Chu et al., 2009 Drug Metab Dispos 37: 1339-1354), the most commonly used and recommended experimental protocol for assessing enzyme induction in regulatory submissions involves the use of primary human hepatocytes and evaluates catalytic activity and mRNA levels for three cytochrome P450 isoforms, CYP1A2, CYP2B6 and CYP3A4. For many years now, Cyprotex has offered a high quality and popular cytochrome P450 induction service to evaluate catalytic activity. As a consequence of the PhRMA perspective paper and other publications, we have extended our offering to include evaluation of mRNA assessment in addition to catalytic activity for CYP1A2, CYP2B6 and CYP3A4. As with all our services on offer at Cyprotex, the new assay has been fully validated and meets the high quality expected by our customers.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments on the launch of the improved service. "By developing our cytochrome P450 induction service to evaluate mRNA levels in addition to catalytic activity, it will enable us to keep up-to-date with the industry requirements in this area. The introduction of this service is part of our expansion of our Cloe® Select portfolio of services focusing on later stage assays.’
For further information:
Helen Gill PhD, Product Development Manager
Tel: +44 (0)1625 505 100